ReviewExpert opinion on drug delivery2015
Long-term delivery of protein therapeutics.
Review in Expert opinion on drug delivery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Dual-Stimuli Responsive Poly(N-acryloyl glycine) Microgels: Investigation of Network Structures and Application for Loading and Release of Biologics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Protein Delivery Using Three-Dimensional Printing of Buccal Films: Technological Advances and Clinical Potential.Pharmaceutics · 2026Review
- Advances in GelMA Hydrogel-Enabled Angiogenic-Osteogenic Coupling: From Structural Programming to Exogenous Cue Synergy.Journal of functional biomaterials · 2026Review
- A Novel Non-Aqueous Emulsification Platform to Fabricate Polymeric Microspheres for Sustained Delivery of Biologics.Pharmaceutical research · 2026Article
- Coding circular RNA in human cancer.Genes & diseases · 2025Review
- Long-term interleukin-4 release from 3D printable affinity hydrogels promotes M2-like macrophage polarisationBiomaterials science · 2025Article
- Engineering Cell-Specific Protein Delivery Vehicles for Erythroid Lineage Cells.ACS bio & med chem Au · 2025Article
- Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.Drug delivery and translational research · 2025Review
- Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics.Chemical reviews · 2025Review
- Actuation-Mediated Compression of a Mechanoresponsive Hydrogel by Soft Robotics to Control Release of Therapeutic Proteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Spinorphin Molecules as Opportunities for Incorporation into Spinorphin@AuNPs Conjugate Systems for Potential Sustained Targeted Delivery to the Brain.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Revolutionizing Heart Failure Therapy: Harnessing IVT mRNA and Fusion Protein Technology to Prolong rhBNP Half-Life.Pharmaceutical research · 2025Article
- The influence of the pharmaceutical industry on the development of gonadotrophins and ovarian stimulation protocols in assisted reproductive technologies.Frontiers in endocrinology · 2025Review
- Effective Strategies in Designing Chitosan-hyaluronic Acid Nanocarriers: From Synthesis to Drug Delivery Towards Chemotherapy.Current drug delivery · 2025Review
- Hydrolytically Degradable Zwitterionic Polyphosphazene Containing HEPES Moieties as Side Groups.Biomacromolecules · 2024Article
- Immunotherapies for locally aggressive cancers.Advanced drug delivery reviews · 2024Review
- Biomaterials for Protein Delivery: Opportunities and Challenges to Clinical Translation.Micromachines · 2024Review
- Biodegradable Long-Acting Injectables: Platform Technology and Industrial Challenges.Handbook of experimental pharmacology · 2024Article
- Challenges and Therapeutic Approaches for the Protein Delivery System: A Review.Pharmaceutical nanotechnology · 2024Review
- Therapeutic Fusion Proteins.The AAPS journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionProteins are effective biotherapeutics with applications in diverse ailments. Despite being specific and potent, their full clinical potential has not yet been realized. This can be attributed to short half-lives, complex structures, poor in vivo stability, low permeability, frequent parenteral administrations and poor adherence to treatment in chronic diseases. A sustained release system, providing controlled release of proteins, may overcome many of these limitations. AREAS COVERED: This review focuses on recent development in approaches, especially polymer-based formulations, which can provide therapeutic levels of proteins over extended periods. Advances in particulate, gel-based formulations and novel approaches for extended protein delivery are discussed. Emphasis is placed on dosage form, method of preparation, mechanism of release and stability of biotherapeutics. EXPERT OPINION: Substantial advancements have been made in the field of extended protein delivery via various polymer-based formulations over last decade despite the unique delivery-related challenges posed by protein biologics. A number of injectable sustained-release formulations have reached market. However, therapeutic application of proteins is still hampered by delivery-related issues. A large number of protein molecules are under clinical trials, and hence, there is an urgent need to develop new methods to deliver these highly potent biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.